marcus_saemann
@MarcusSaemannInternal medicine=Nephrology, Diabetes, Immunology, literature/music/tennis, R. Federer, L.v.Mises, Vienna & J.Haydn aficionado
Similar User
@EllerKathrin
@sa_nephro
@idlake
@dgfn_ev
@AKronbichler
@BondGregor
@lowcarb_mark
@drtroystapleton
@Christo46109236
@MaCamilabt
@odlerb
@dellep_sergio
@scottmorgan88
@e_zitt
@Nephr0s
SGLT2 Inhibitor #SGLT2i in #Diabetic and #NonDiabetic Renal #Transplant Recipients #VisualAbstract by @DrPSVali kireports.org/article/S2468-…
Eureka! MARKUS at HOMe's Top 10 List of most important trials in cardiology & lipidology in 2024 is completed. We present our Top 10 Friday before Christmas. Academic guests: @JaninePoss @m_leistner Ulrich Laufs Hosts: @floriancustodis @StephanSchirme1 @MarcusSaemann Insa Emrich
T3g #nephjc ACCORD: No CV benefit from intensive BP control in T2D SPRINT:⬇️CV risk in non-DM pts with intensive BP control ESPRIT:⬇️ CV events with intensive BP control, regardless of DM history BPROAD: benefit in DM pts, ⬇️ stroke (HR 0.79, 0.67–0.92), NO diff in all-cause ☠️
Is Finerenone just an expensive spironolactone? "A RCT of nonsteroidal versus steroidal MRAs is desperately needed in the HF population" Thanks for your thoughtful Editorial, @NealDixit and Saul Schaefer! @dgfn_ev @YoungDgk @MarcusSaemann @hswapnil ahajournals.org/doi/10.1161/CI…
Albuminuria testing is an easy way to identify, early on, a higher risk of cardiovascular and kidney morbidity and mortality in patients at-risk. This study found that general practitioners (GPs) were aware of guideline recommendations to screen for albuminuria in patients with…
It has been a great ride but it is time to move on. Look for me (along with the rest of #MedTwitter and #NephTwitter) at bsky.app/profile/kidney…
Vamos, @RafaelNadal! As you get ready to graduate from tennis, I’ve got a few things to share before I maybe get emotional. Let’s start with the obvious: you beat me—a lot. More than I managed to beat you. You challenged me in ways no one else could. On clay, it felt like I…
After PARADISE-MI, EMPACT-MI, DAPA-MI, here comes more CLEAR Evidence: HF Drugs are not automacally post-MI Drugs. Sacubitril, SGLT-2 and Spironolactone all improve prognosis in HFREF - but not in post-MI pat. @SanjitSJolly nejm.org/doi/full/10.10…
Until this morning, we considered Semaglutid as peak of pharmacotherapy in cardio-renal disease. Today, tirzepatide has become the new SUMMIT. @YoungDgk @MarcusSaemann @floriancustodis @leistner @m_leistner @luisbeckdasilva @dguerrot @dgfn_ev nejm.org/doi/full/10.10…
48 % less AVF thrombosis with Apixaban after thrombectomy of hemodialysis vascular access in a Taiwanese RCT - Time to change our practice? @isabellemahe1 @LaurentBertole1 @bbikdeli @IsthPresident @isth @dgfn_ev @oegnephro @com_SFNDT
EASi to strengenth the evidence for the 4th pillar in Nephroprotection? Arguably the Top Kidney Trial of the late Twenties! Dr Parminder Judge @KatherineTuttl8 @doreen_zhu @willkidney @RichardHaynes3 @MartinLandray Trial design: academic.oup.com/ndt/article/do…… @NDTsocial @hjanders_hans
🎾🇨🇭🥹 Roger having a hit while on holiday in Africa 📸 Roger Federer IG
We have data demonstrating GLP1 benefit in diabetic kidney disease, but what about non-diabetic kidney disease? 🤔 Enter the SMART trial which enrolled adults with BMI >27 and non-diabetic CKD and randomized to semaglutide vs. placebo Baseline BMI 36, GFR 65, urine albumin to…
I truly do not think anybody loves the organ they specialize in more than nephrologists love the kidney
Unedited love song for the kidneys during #nephjc party #kidneywk All the applause go to @Maximal_Change
SAFE-D finally published: In a short-term feasability study, VKA again turns out to be a "No-Go" in CKD G5-AF, and no OAC seems more attractive than apixaban (admittedly, with a 2 * 5 mg option, while we favor 2 * 2,5 mg). Thanks, @brendanjsmyth @Badves @matthewweir @DrRonWald
Awaiting @Dan_Fuster's interventional SWEET STONE trial: Here comes more epidemiological data that SGLT-2 may substantially lower the burden of nephrolithiasis - here studied in patients with prevalent stone disease @natalie_mccor @dgfn_ev @MarcusSaemann bmj.com/content/387/bm…
CKD arguably the most consequential common comorbidity in heart failure, accounting for >2x rehospitalisations than any other condition UK data from almost 1/4 million people, now open access online in @LancetGH, from @Fletcher_RA and our team: thelancet.com/journals/lanpu…
Whole pop UK linked data on >230,000 ppl with HF from @Fletcher_RA at #ESCCongress - Ppl with CKD remain undertreated for HF despite being at 🔼 risk - CKD contributes 2x to 🏥/☠️ than any other comorbidity - Major opportunities to improve pop health In press, @TheLancetPH
Epidemiological Danish Dynamite from @BNordestgaard & CGPS team CKD Begets High Remnant Cholesterol High Remnant Cholesterol Begets ASCVD @dgfn_ev @oegnephro @com_SFNDT @floriancustodis @fleig_s @dguerrot ahajournals.org/doi/10.1161/AT…
United States Trends
- 1. Lions 75 B posts
- 2. Josh Allen 20,6 B posts
- 3. Steelers 50,7 B posts
- 4. Eagles 59,5 B posts
- 5. Colts 17 B posts
- 6. Broncos 21,5 B posts
- 7. Najee 4.520 posts
- 8. Bo Nix 5.469 posts
- 9. Jalen 27,4 B posts
- 10. #iskalovefsocietykod N/A
- 11. Jonathan Taylor 2.351 posts
- 12. Mike Evans 3.090 posts
- 13. #OnePride 8.795 posts
- 14. #BUFvsDET 9.636 posts
- 15. Drake Maye 2.962 posts
- 16. TJ Watt 3.587 posts
- 17. #HereWeGo 6.726 posts
- 18. Tony Romo 1.367 posts
- 19. Tyler Bass 1.155 posts
- 20. Buffalo 17,4 B posts
Who to follow
-
Kathrin Eller
@EllerKathrin -
SANephrology
@sa_nephro -
Ian Lake
@idlake -
Deutsche Gesellschaft für Nephrologie (DGfN) e.V.
@dgfn_ev -
Andreas Kronbichler
@AKronbichler -
Gregor Bond
@BondGregor -
Mark Hancock
@lowcarb_mark -
Troy stapleton
@drtroystapleton -
Christoph Schwarz MD
@Christo46109236 -
Maria Camila Bermudez MD
@MaCamilabt -
Balazs Odler
@odlerb -
Sergio Dellepiane
@dellep_sergio -
Scott Morgan
@scottmorgan88 -
Emanuel Zitt
@e_zitt -
Marco Bonilla
@Nephr0s
Something went wrong.
Something went wrong.